AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30819689 — intervention group
Group type: EXPERIMENTAL
Intervention: Darkroom prone provocative testing (DRPPT) among PACS with two or three quadrants closed
Number of subjects: 889
Study 30059794 — intervention group
Group type: EXPERIMENTAL
Intervention: d-cycloserine
Number of subjects: 0
Study 30059794 — intervention group
Group type: EXPERIMENTAL
Intervention: alprazolam
Number of subjects: 0
Study 30059794 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 30059794 — intervention group
Group type: EXPERIMENTAL
Intervention: medications (d-cycloserine, alprazolam)
Number of subjects: 0
Study 27716159 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid injection (20 mg Depo-Medrone)
Number of subjects: 240
Study 27716159 — intervention group
Group type: COMPARATOR
Intervention: Night splint
Number of subjects: 240
Study 24844787 — intervention group
Group type: EXPERIMENTAL
Intervention: PC-SOD (80 mg, intravenous)
Number of subjects: 80
Study 24844787 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intravenous)
Number of subjects: 80
Study 22957904 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxazepam
Number of subjects: 81
Study 22957904 — intervention group
Group type: EXPERIMENTAL
Intervention: L-dopa
Number of subjects: 81
Study 22957904 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 19497461 — intervention group
Group type: EXPERIMENTAL
Intervention: Triage Stroke Panel (D‐dimer, B‐natriuretic peptide, matrix metalloproteinase 9, and S‐100beta)
Number of subjects: 204
Study 19497461 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of nurse assessment and MMX result
Number of subjects: 204
Study 19497461 — intervention group
Group type: COMPARATOR
Intervention: Nurse assessment only
Number of subjects: 204
Study 21415613 — intervention group
Group type: EXPERIMENTAL
Intervention: TEAMcare intervention
Number of subjects: 214
Study 21415613 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 214
Study 15763450 — intervention group
Group type: EXPERIMENTAL
Intervention: montelukast group (n:58)
Number of subjects: 117
Study 15763450 — intervention group
Group type: COMPARATOR
Intervention: control group (n:59)
Number of subjects: 117
Study 12635467 — intervention group
Group type: EXPERIMENTAL
Intervention: Step aerobic training (StA)
Number of subjects: 40
Study 12635467 — intervention group
Group type: COMPARATOR
Intervention: Cycle ergometer training (CET)
Number of subjects: 40
Study 10624646 — intervention group
Group type: COMPARATOR
Intervention: Promethazine 25 mg (Group 2)
Number of subjects: 87
Study 10624646 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron 2 mg plus promethazine 12.5 mg (Group 3, combination)
Number of subjects: 87
Study 10624646 — intervention group
Group type: COMPARATOR
Intervention: Combination (ondansetron 4 mg and promethazine 25 mg)
Number of subjects: 87
Study 7555933 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection sclerotherapy (1% polidocanol)
Number of subjects: 315
Study 7555933 — intervention group
Group type: COMPARATOR
Intervention: Laser photocoagulation (Nd:YAG laser)
Number of subjects: 315
Study 7555933 — intervention group
Group type: COMPARATOR
Intervention: Laser photocoagulation
Number of subjects: 315
Study 7555933 — intervention group
Group type: COMPARATOR
Intervention: Injection sclerotherapy and laser photocoagulation
Number of subjects: 315
Study 7555933 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection sclerotherapy
Number of subjects: 315
Study 1780416 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver acetate chewing gum
Number of subjects: 496
Study 1780416 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine chewing gum
Number of subjects: 496
Study 1780416 — intervention group
Group type: COMPARATOR
Intervention: Ordinary chewing gum
Number of subjects: 496
Study 1780416 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatments (Nicotine, Silver Acetate, Ordinary chewing gum)
Number of subjects: 496
Study 1780416 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 496
Study 7204955 — intervention group
Group type: COMPARATOR
Intervention: Task instructions indicating Easy or Hard (Subjective) and actual task difficulty (Easy or Hard) (Objective)
Number of subjects: 0
Study 30138239 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-minute intermaximal repetition rest period (IMRRP-3)
Number of subjects: 9
Study 30138239 — intervention group
Group type: COMPARATOR
Intervention: 2-minute intermaximal repetition rest period (IMRRP-2)
Number of subjects: 9
Study 28791802 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified-release prednisone (Lodotra™)
Number of subjects: 12
Study 28791802 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release prednisolone
Number of subjects: 12
Study 28791802 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 12
Study 26966106 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate
Number of subjects: 62
Study 26966106 — intervention group
Group type: COMPARATOR
Intervention: Thiopental
Number of subjects: 62
Study 24080993 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (AA) 1000 mg plus prednisone 5 mg b.i.d.
Number of subjects: 797
Study 24080993 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus prednisone 5 mg b.i.d.
Number of subjects: 797
Study 24080993 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (AA) plus prednisone
Number of subjects: 797
Study 23419915 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapists' estimations of therapy time
Number of subjects: 12
Study 23419915 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapists' estimations of inactive time
Number of subjects: 12
Study 23419915 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean difference between therapist-estimated and video-recorded total therapy time
Number of subjects: 12
Study 23419915 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean difference between therapist-estimated and video-recorded active time
Number of subjects: 12
Study 23419915 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean difference between therapist-estimated and video-recorded inactive time
Number of subjects: 12
Study 23419915 — intervention group
Group type: COMPARATOR
Intervention: Comparison of estimation accuracy between individual therapy sessions and circuit class therapy
Number of subjects: 12
Study 20713475 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily budesonide/formoterol (80/4.5 microg x2 inhalations; 160/9 microg daily)
Number of subjects: 521
Study 20713475 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily budesonide/formoterol (40/4.5 microg x2 inhalations; 160/18 microg daily)
Number of subjects: 521
Study 18160245 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision Aid (DA)
Number of subjects: 194
Study 18160245 — intervention group
Group type: COMPARATOR
Intervention: Control group (no DA)
Number of subjects: 194
Study 15690290 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS monitoring
Number of subjects: 16
Study 15690290 — intervention group
Group type: COMPARATOR
Intervention: Clinical sedation scales (OAA/S, Modified Ramsey, VAS)
Number of subjects: 16
Study 12757961 — intervention group
Group type: EXPERIMENTAL
Intervention: Marijuana cigarette (0.003, 2, or 3.5% delta‐9 tetrahydrocannabinol [THC]) after partial sleep deprivation (PSD)
Number of subjects: 7
Study 12757961 — intervention group
Group type: EXPERIMENTAL
Intervention: Marijuana cigarette (0.003, 2, or 3.5% delta‐9 tetrahydrocannabinol [THC]) after regular sleep
Number of subjects: 7
Study 12757961 — intervention group
Group type: EXPERIMENTAL
Intervention: Marijuana cigarette (2% THC) after PSD
Number of subjects: 7
Study 12757961 — intervention group
Group type: EXPERIMENTAL
Intervention: Marijuana cigarette (3.5% THC) after PSD
Number of subjects: 7
Study 12757961 — intervention group
Group type: EXPERIMENTAL
Intervention: High‐potency marijuana
Number of subjects: 7
Study 12757961 — intervention group
Group type: EXPERIMENTAL
Intervention: Marijuana or PSD
Number of subjects: 7
Study 10540058 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal diclofenac 100 mg immediately post-induction
Number of subjects: 0
Study 8871583 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading aloud a piece of text (task a)
Number of subjects: 13
Study 8871583 — intervention group
Group type: COMPARATOR
Intervention: Reading silently (task b)
Number of subjects: 13
Study 8871583 — intervention group
Group type: EXPERIMENTAL
Intervention: Speaking spontaneously (task c)
Number of subjects: 13
Study 8871583 — intervention group
Group type: COMPARATOR
Intervention: Making sounds without speaking (task d)
Number of subjects: 13
Study 1751464 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% ofloxacin
Number of subjects: 84
Study 1751464 — intervention group
Group type: COMPARATOR
Intervention: 0.5% chloramphenicol
Number of subjects: 84
Study 7006789 — intervention group
Group type: EXPERIMENTAL
Intervention: CCNU (100 mg/m2 p.o. q. 6 weeks)
Number of subjects: 60
Study 7006789 — intervention group
Group type: COMPARATOR
Intervention: BCNU (200 mg/m2 p. 6 weeks)
Number of subjects: 60
Study 7006789 — intervention group
Group type: EXPERIMENTAL
Intervention: CCNU
Number of subjects: 60
Study 7006789 — intervention group
Group type: COMPARATOR
Intervention: BCNU
Number of subjects: 60
Study 7006789 — intervention group
Group type: EXPERIMENTAL
Intervention: Responders
Number of subjects: 60
Study 7006789 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-responders
Number of subjects: 60
Study 7006789 — intervention group
Group type: EXPERIMENTAL
Intervention: CCNU and BCNU
Number of subjects: 60
Study 30767788 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrulline (2 g/day)
Number of subjects: 50
Study 30767788 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 29717699 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Management education (SMILE (UK))
Number of subjects: 404
Study 29717699 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 404
Study 26214075 — intervention group
Group type: EXPERIMENTAL
Intervention: Olfactory prime (clean, citrus smell)
Number of subjects: 0
Study 26214075 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual prime (male eyes)
Number of subjects: 0
Study 26214075 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual prime (female eyes)
Number of subjects: 0
Study 24816219 — intervention group
Group type: EXPERIMENTAL
Intervention: Antitachycardia pacing (ATP)
Number of subjects: 286
Study 24816219 — intervention group
Group type: EXPERIMENTAL
Intervention: Antitachycardia pacing (ATP) with DN ≥ 50 milliseconds
Number of subjects: 286
Study 24816219 — intervention group
Group type: EXPERIMENTAL
Intervention: Antitachycardia pacing (ATP) with DN < 50 milliseconds
Number of subjects: 286
Study 24816219 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall study population
Number of subjects: 286
Study 23010339 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad-spectrum antibiotic treatment for 48 hours
Number of subjects: 46
Study 23010339 — intervention group
Group type: COMPARATOR
Intervention: Broad-spectrum antibiotic treatment for 7 days
Number of subjects: 46
Study 20363908 — intervention group
Group type: EXPERIMENTAL
Intervention: Materialistic pursuits
Number of subjects: 0
Study 20363908 — intervention group
Group type: COMPARATOR
Intervention: Experiential pursuits
Number of subjects: 0
Study 20363908 — intervention group
Group type: EXPERIMENTAL
Intervention: Materialistic purchases
Number of subjects: 0
Study 20363908 — intervention group
Group type: EXPERIMENTAL
Intervention: Materialistic people
Number of subjects: 0
Study 18375021 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV7 (7-valent pneumococcal conjugate vaccine) administered > or =7 days before DTaP
Number of subjects: 800
Study 18375021 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV7 (7-valent pneumococcal conjugate vaccine) administered with DTaP
Number of subjects: 800
Study 18375021 — intervention group
Group type: COMPARATOR
Intervention: DTaP only
Number of subjects: 800
Study 15671975 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous glycopyrrolate
Number of subjects: 38
Study 15671975 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline solution)
Number of subjects: 38
Study 12789978 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonicare toothbrush
Number of subjects: 0
Study 10321444 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine-metoprolol 5/50 mg o.d. (Logimax)
Number of subjects: 109
Study 10321444 — intervention group
Group type: COMPARATOR
Intervention: Captopril-hydrochlorothiazide 25/25 mg o.d. (Capozide)
Number of subjects: 109
Study 10321444 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine-metoprolol 10/100 mg o.d. (Logimax)
Number of subjects: 109
Study 10321444 — intervention group
Group type: COMPARATOR
Intervention: Captopril-hydrochlorothiazide 50/25 mg o.d. (Capozide)
Number of subjects: 109
Study 7900559 — intervention group
Group type: EXPERIMENTAL
Intervention: Doyle II silicone stents
Number of subjects: 20
Study 7900559 — intervention group
Group type: COMPARATOR
Intervention: Nasal packing (from 1989 study)
Number of subjects: 20
Study 2672775 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthotopic liver transplantation
Number of subjects: 0
Study 907011 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructional manuals alone
Number of subjects: 160
Study 907011 — intervention group
Group type: EXPERIMENTAL
Intervention: Training groups
Number of subjects: 160
Study 907011 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone consultations
Number of subjects: 160
Study 907011 — intervention group
Group type: EXPERIMENTAL
Intervention: Training groups plus home visits
Number of subjects: 160
Study 907011 — intervention group
Group type: COMPARATOR
Intervention: Delayed-treatment control group
Number of subjects: 160
Study 30740658 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions based on gait analysis (including physical therapy, orthotics, spasticity management, and orthopedic surgery)
Number of subjects: 60
Study 30740658 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 60
Study 28320541 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac (20 mg)
Number of subjects: 92
Study 28320541 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (30 mg)
Number of subjects: 92
Study 28320541 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 25869627 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of cycloserine (250, 500, or 1000 mg)
Number of subjects: 12
Study 25869627 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple doses of cycloserine 250 mg BID for 5 days
Number of subjects: 12
Study 25869627 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 12
Study 23700804 — intervention group
Group type: EXPERIMENTAL
Intervention: Submandibular gland transfer
Number of subjects: 65
Study 23700804 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 65
Study 21091100 — intervention group
Group type: COMPARATOR
Intervention: Baseline BMI
Number of subjects: 83
Study 21091100 — intervention group
Group type: COMPARATOR
Intervention: Skinfold thickness
Number of subjects: 83
Study 21091100 — intervention group
Group type: COMPARATOR
Intervention: Changes in BMI
Number of subjects: 83
Study 21091100 — intervention group
Group type: COMPARATOR
Intervention: Changes in waist circumference
Number of subjects: 83
Study 21091100 — intervention group
Group type: COMPARATOR
Intervention: Baseline CRF
Number of subjects: 83
Study 19625125 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine (60-120 mg/day)
Number of subjects: 231
Study 19625125 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 231
Study 17277995 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Navigator (PN)
Number of subjects: 125
Study 17277995 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (C)
Number of subjects: 125
Study 15144908 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone (800 microg/d for 12 weeks)
Number of subjects: 45
Study 11977322 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD patients
Number of subjects: 41
Study 11977322 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 41
Study 9701895 — intervention group
Group type: EXPERIMENTAL
Intervention: Haematinic supplementation for 8 weeks
Number of subjects: 300
Study 9701895 — intervention group
Group type: EXPERIMENTAL
Intervention: Haematinic supplementation
Number of subjects: 300
Study 8273133 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO 150 units/kg
Number of subjects: 116
Study 8273133 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO 300 units/kg
Number of subjects: 116
Study 8273133 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO 600 units/kg
Number of subjects: 116
Study 8273133 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 8273133 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO (all doses)
Number of subjects: 116
Study 2528983 — intervention group
Group type: EXPERIMENTAL
Intervention: h alpha CGRP infusion (1.5 micrograms min‐1 i.v.)
Number of subjects: 10
Study 2528983 — intervention group
Group type: COMPARATOR
Intervention: Glyceryl trinitrate (GTN)
Number of subjects: 10
Study 818752 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenine arabinoside (Ara‐A)
Number of subjects: 0
Study 30998610 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary thrombolysis (IT group)
Number of subjects: 71
Study 30998610 — intervention group
Group type: COMPARATOR
Intervention: Thrombus aspiration (TA group)
Number of subjects: 71
Study 28887378 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation
Number of subjects: 3876
Study 28887378 — intervention group
Group type: COMPARATOR
Intervention: Continued smoking
Number of subjects: 3876
Study 26256216 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpharmacologic therapies (NPTs) provided to nursing home residents, including an online course for physicians and a 1-day seminar for nurses.
Number of subjects: 239
Study 26256216 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic NPT prescribed by physicians.
Number of subjects: 239
Study 26256216 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing education on pain-management techniques.
Number of subjects: 239
Study 26256216 — intervention group
Group type: EXPERIMENTAL
Intervention: NPT received by residents.
Number of subjects: 239
Study 24054342 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive daily symptom diary intervention with self-care education and counseling at baseline and 5 follow-up calls for 3 months
Number of subjects: 44
Study 24054342 — intervention group
Group type: COMPARATOR
Intervention: Usual-care group
Number of subjects: 44
Study 22287401 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated bolus injections (40 mg dose, twice per day)
Number of subjects: 32
Study 22287401 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion (80 mg per day mixed with 5% glucose)
Number of subjects: 32
Study 22287401 — intervention group
Group type: EXPERIMENTAL
Intervention: Both administration methods (repeated bolus and continuous infusion)
Number of subjects: 32
Study 19429721 — intervention group
Group type: EXPERIMENTAL
Intervention: Endobronchial ultrasound (EBUS)
Number of subjects: 58
Study 19429721 — intervention group
Group type: COMPARATOR
Intervention: High‐resolution CT (HRCT) scanning
Number of subjects: 58
Study 16394797 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon and ribavirin treatment in IVDUs
Number of subjects: 406
Study 12699093 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic repair under general anaesthesia (n = 237)
Number of subjects: 471
Study 12699093 — intervention group
Group type: COMPARATOR
Intervention: Mesh plug insertion under monitored local, epidural, or spinal anaesthesia (n = 234)
Number of subjects: 471
Study 10499944 — intervention group
Group type: EXPERIMENTAL
Intervention: ST-segment elevation measurements by emergency physicians, residents, and students
Number of subjects: 52
Study 10499944 — intervention group
Group type: EXPERIMENTAL
Intervention: Threshold of at least 2.0 mm for ST-segment elevation
Number of subjects: 52
Study 10499944 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraobserver measurements of paired ST-segment elevations
Number of subjects: 52
Study 8750275 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy and autologous bone marrow support (ABMS) without induction chemotherapy (Upfront cohort)
Number of subjects: 64
Study 8750275 — intervention group
Group type: COMPARATOR
Intervention: Induction chemotherapy with doxorubicin, 5-fluorouracil and methotrexate prior to high-dose chemotherapy and ABMS (AFM cohort)
Number of subjects: 64
Study 1776388 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline (30 mg/day for 8 weeks)
Number of subjects: 18
Study 1776388 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for 4 weeks)
Number of subjects: 18
Study 7008941 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin
Number of subjects: 0
Study 7008941 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6329980 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg X 2/die) and sucralfate (1 gr X 2/die)
Number of subjects: 25
Study 6329980 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine only
Number of subjects: 25
Study 6329980 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 1 g/day
Number of subjects: 25
Study 6329980 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 800 mg/b.i.d.
Number of subjects: 25
Study 6329980 — intervention group
Group type: COMPARATOR
Intervention: Sucralfate 3 g/day
Number of subjects: 25
Study 6329980 — intervention group
Group type: COMPARATOR
Intervention: Pirenzepine 150 mg/day
Number of subjects: 25
Study 6329980 — intervention group
Group type: COMPARATOR
Intervention: Sulglycotide 0.5‐1 g/day
Number of subjects: 25
Study 6329980 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 29460914 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid
Number of subjects: 0
Study 29460914 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27663365 — intervention group
Group type: EXPERIMENTAL
Intervention: Adipose-derived MSCs
Number of subjects: 15
Study 27663365 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow-derived MSCs
Number of subjects: 15